Trial Profile

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients With Advanced Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CTX-8371 (Primary)
Indications Head and neck cancer; Hodgkin's disease; Hypopharyngeal cancer; Laryngeal cancer; Malignant melanoma; Non-small cell lung cancer; Oropharyngeal cancer; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; First in man
Sponsors Compass Therapeutics

08 May 2025 Results (toxicity data) presented in a Compass Therapeutics media release
08 May 2025 According to a Compass Therapeutics media release, company advanced the Phase 1 dose-escalation study of CTX-8371 and evaluating the fourth dosing cohort with preliminary data. The company looks forward to sharing data from the study later this year.
30 Apr 2025 Trial design presented at the 116th Annual Meeting of the American Association for Cancer Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com